Chinese Heparin Subject Of U.S. Congress Hearing
This article was originally published in PharmAsia News
Executive Summary
The CEO of Baxter International is set to testify before a congressional hearing April 29 on the firm's contaminated heparin from China. Baxter's version of the blood thinner was linked to at least 81 deaths, the problem traced to a single source in China and said to have been deliberate. The title of the House Oversight and Investigations Subcommittee hearing is, "The Heparin Disaster: Chinese Counterfeits and American Failures." Baxter CEO Robert Parkinson and the CEO of the Chinese supplier, Scientific Protein Labs, were on the witness list. (Click here for more
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.